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SUBSTRATES  OF  HAGEMAN  FACTOR 
I. Isolation  and Characterization of Human Factor XI (PTA)  and 
Inhibition  of the Activated  Enzyme by al-Antitrypsin 
BY LOUIS W. HECK  AND ALLEN P.  KAPLAN 
(From  the Allergic Diseases Section, Laboratory of Clinical Investigation, National Institute of 
Allergy and Infectious Diseases,  National Institutes of Health, Bethesda, Maryland 20014) 
The contribution of a  coagulation factor to the enzymatic cascade known as the intrinsic 
coagulation pathway is dependent upon its rate of activation and the rate of destruction of 
the activated enzyme. Considerable progress has recently been made in our understanding 
of  the  mechanism  of  activation  and  inhibition  of  coagulation  Factor  XI  or  partial 
thromboplastin  antecedent  (PTA). 1  Activation  of  the  precursor  form  (Pre-PTA)  is 
dependent  upon  contact  activation of Hageman  factor  (1)  as well as upon  a  feedback 
mechanism  in  which  a  second  Hageman  factor substrate,  prekallikrein, is activated to 
kallikrein (2) which in turn further activates Hageman factor (3). In the absence of this 
intrinsic control (Fletcher factor or prekallikrein deficiency) (4), the rate of activation of 
Hageman factor and, in turn, pre-PTA is diminished (5). Once activated, PTA is known to 
be inhibited by the inhibitor of the activated first component of complement (CT INH) (6) 
as well as by antithrombin III (7). 
In  this  manuscript  we  describe a  method  for the  purification of pre-PTA  which 
separates  it from  other identifiable proteins and  demonstrate  that  it is directly 
converted  to  activated  PTA  by  incubation  with  trace  quantities  of activated 
Hageman  factor or Hageman  factor prealbumin  fragments.  When we sought the 
plasma  inhibitors of activated  PTA,  a  new  a 1-globulin PTA  inhibitor of mol wt 
65,000  was  isolated and identified as al-antitrypsin. 
Materials and Methods 
Bradykinin triacetate (Sandoz Pharmaceuticals, Ltd., Basel, Switzerland} was used as the standard 
for  native bradykinin. Hexadimethrine bromide (Aldrich Chemical Co.,  Inc.,  Milwaukee, Wis.), 
enzodiffusion fibrin plates and streptokinase (Hyland Division, Travenol Laboratories, Inc., Costa 
Mesa,  Calif.), hemostatic  phosphatide (cephalin)  and  benzoyl-d,l-arginine-p-nitroanilide  (Nutri- 
tional Biochemical Corp., Cleveland, Ohio}, arantitrypsin immunodiffusion plates (Meloy Laborato- 
ries, Inc., Springfield, Va.), concanavalin A Sepharose (Pharmacia Fine Chemicals, Inc., Piscataway, 
N.  J.),  and antisera to IgG, /3~-glycoprotein I, al-antitrypsin, a~-macroglobulin, C~ INH,  a~-anti- 
1Abbreviations  used in this paper:  CI INH, inhibitor of the activated first component of comple- 
ment; CM,  carhoxymethyl; PTA, partial thromboplastin antecedent; PTC,  plasma thromboplastin 
component; PTT, partial thromhoplastin time; QAE, quaternary aminoethyl; SDS, sodium dodeeyl 
sulfate; SP, sulphopropyl. 
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thrombin (antithrombin III), a ~-antichymotrypsin and inter-a-trypsin inhibitor (Behring Diagnostics, 
Inc., Woodbury, N. Y.)  soybean, lima bean, and ovomucoid trypsin inhibitors (Sigma Chemical Co., 
St. Louis, Mo.) were obtained as indicated. 
Hageman factor-deficient plasma, PTA-deficient plasma, and plasma thromboplastin component 
(PTC)-deficient plasmas were obtained from Sera-Tec Biologicals, New Brunswick,  N.  J.  al-anti- 
trypsin-deficient plasma was a gift from Dr. Charles Reed (University of Wisconsin Medical School, 
Madison, Wis.). Trasylol was provided by Dr. Marion Webster, NIH, Bethesda, Md. 
Preparation and Assay of Plasma Proteins.  Fresh plasma was utilized as the source of Hageman 
factor fragments, pre-PTA, prekallikrein, the Hageman factor dependent plasminogen proactivator, 
a~-macroglobulin, al-antitrypsin, CT INH,  a~-chymotrypsin inhibitor and inter-a-trypsin inhibitor. 
For the preparation of plasma, blood was collected in plastic acid-citrate dextrose packs which were 
made 360 #g/ml in hexadimethrine bromide (36 mg/ml solution in 0.15 M saline) to inhibit activation 
of Hageman factor. The blood was centrifuged at 900 g for 20 min at 4°C and the plasma separated 
with plastic pipettes.  Plastic columns were  utilized throughout all chromatographic procedures to 
minimize activation of Hageman factor. However, glass tubes were used to collect the fractions unless 
unactivated Hageman factor was sought (5). Samples were concentrated by ultrafiltration through a 
UM-10 membrane (Amicon Corp., Lexington, Mass.). 
Alkaline disc gel electrophoresis and isoelectric focusing in polyacrylamide gels were performed as 
previously described (2, 8). 71/2% acrylamide gels containing 0.1% sodium dodecyl sulfate (SDS) were 
prepared and run according to the method of Weber and Osborn (9) in glass tubes measuring 5 mm × 
125 mm. An anti-IgG immunoadsorbant consisting of rabbit antibody to human IgG coupled to 6B 
Sepharose was prepared as previously described (10). The column was run in 0.003 M  PO4 buffer 
containing  0.35  M  sodium  chloride  and  all  samples  were  dialyzed  against  this  buffer  before 
application to the column. Use of this higher ionic strength buffer was found to minimize nonspecific 
adsorption to the column and did not interfere with the binding of the IgG. Protein quantitation on a 
weight basis was determined by micro-Kjeldahl analysis. 
Purification of Human Pre-PTA.  2,500 ml of human plasma was dialyzed for 12 h against three 
changes of 0.003  M  PO,  buffer  pH  8.3  and  applied  to  a  15  cm  x  100  cm  column  of quaternary 
aminoethyl  (QAE)  Sephadex  equilibrated  with  the  same  buffer.  The  effluent  containing three 
Hageman factor substrates, pre-PTA, prekallikrein, and plasminogen proactivator (10) was concen- 
trated to 400 ml, the pH brought to 6.0 with 1 N HC1, and the mixture fractionated in a 9 cm x 72 cm 
column of sulphopropyl (SP) Sephadex equilibrated with 0.003 M PO, buffer pH 6.0. The column was 
washed with five liters starting buffer and a gradient of 12 liters starting buffer, and 12 liters 0.003 M 
PO4 buffer pH 6.0 containing 0.35 M NaC1 was applied. Pre-PTA eluted at a conductivity of 21mS at 
the far end of the salt gradient and, as previously reported, was well separated from both prekallikrein 
and  plasminogen  proactivator  (10).  The  pre-PTA  peak  was  then  concentrated  to  5.0  ml  and 
fractionated on a 5 x 100 cm column of Sephadex G-150 equilibrated with 0.003 M PO~ buffer 0.15 M 
NaC1 run at 15 ml/h. Pre-PTA eluted along the ascending limb of the IgG peak at a mol wt of 175,000 
whereas contaminating prekallikrein and plasminogen proactivator eluted later along the descending 
limb of the IgG peak (10).  When the pre-PTA peak was pooled and concentrated to 25 ml, neither 
prekallikrein nor plasminogen proactivator were detected.  When this fraction was further concen- 
trated 10-fold,  prekallikrein and plasminogen proactivator were still not detectable. This pre-PTA 
pool was then passed over the anti-IgG immunoadsorbant and the effluent concentrated to 10 ml. The 
final preparation corrected the PTT of PTA-deficient plasma from a control time of 12 min to 2.5 min 
in the presence of kaolin and gave a PTT of 14 min when tested in the absence of kaolin. No correction 
of the PTT  of PTC  deficient plasma was  observed.  When the purified  material was  assessed  by 
alkaline disc gel electrophoresis and SDS gel electrophoresis, a single band was observed in each gel 
(Fig. 1). The molecular weight of pre-PTA when determined on SDS gels (Fig. 2), revealed a tool wt of 
163,000  based  upon  the  standards  indicated.  When  the  preparation  was  subjected to  isoelectric 
focusing in 4% polyacrylamide gels from pH 7-10, a single band was again obtained (Fig. 3). Elution 
and assay of an unstained gel run simultaneously indicated that this band represented pre-PTA and 
possessed an isoelectric point between pH 8.8 to 9.4,  the peak activity being at pH 9.0 to 9.1. 
PTA Assays.  Pre-PTA was assayed by determining its ability to shorten the partial thromboplas- 
tin time (PTT) of PTA-deficient plasma. 50 ~l PTA source was incubated for 2 min at 37°C with 50 ~l 
"kaolin-cephalin" reagent (20 mg kaolin plus 20 ~l cephalin  [6 mg/ml] in 2 ml phosphate-buffered 
saline) and 50 ul PTA-deficient plasma in 10 x 75 mm plastic tubes. 50 ul 0.05 M CaCl2 was added and LOUIS  W.  HECK  AND ALLEN  P.  KAPLAN  1617 
Fro. 1.  SDS gel electrophoresis (left) and alkaline disc gel electrophoresis at pH 9.3  (right) 
of purified pre-PTA. 
the clotting time determined at room temperature. The tubes were tilted every 30 sec and the end 
point defined as the time interval required for the clot to adhere to the plastic tube. Activated PTA 
was assayed in the same fashion; however, kaolin was then omitted from the cephalin reagent. For 
studies in which inhibition of activated PTA was examined, the inhibitor source was incubated with 
an equal volume of activated PTA for 30 min at 37°C and the residual clotting activity of the PTA was 
determined. The  PTA  content expressed as  a  percentage of normal  plasma was determined by 
comparing the PTT of serial dilutions of the preparation with the PTT of serial dilutions of a pool of 
10 normal plasmas whose PTA content was set at 100%. 
Activated Hageman Factor.  Activated Hageman factor was prepared by sequential chromatogra- 
phy of plasma on  QAE  Sephadex,  Carboxymethyl (CM)  cellulose, Sephadex G-150,  and  diethyl- 
aminoethyl (DEAE) cellulose as previously described (5). The preparation was active upon all three 
Hageman factor substrates, pre-PTA, prekallikrein, and plasminogen proactivator. When utilized at 
a concentration of 15 ~g/ml, it corrected the coagulation defect of Hageman factor-deficient plasma 
from a control time of 30 min to 1 min 40 sec in the presence or absence of kaolin indicating that the 
preparation was completely activated. Its coagulation and kinin-generating activity were associated 
with a  band observed in the cathodal region of an  alkaline disc gel and revealed no evidence of 
fragmentation. It had no effect upon PTA-deficient plasma. 
Hageman  Factor Fragments.  The  Hageman  factor  prealbumin  fragments  were  purified  by 
chromatography of plasma on QAE Sephadex followed by rechromatography on QAE Sephadex, SP 
Sephadex, Sephadex G-100,  and elution from alkaline disc gels after electrophoresis as previously 1618  SUBSTRATES  OF HAGEMAN  FACTOR. I 
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Fro.  2.  Molecular  weight  estimation of pre-PTA as  assessed  by SDS  gel electrophoresis. 
Standards  utilized were human IgG  (160,000), human albumin (68,000), and ovalbumin 
(45,000). 
described  (2). After extensive dialysis the fragments were concentrated by ultrafiltration and were 
routinely utilized at 25 #g/ml. When assayed functionally,  5 ttl of Hageman factor fragment generated 
100 ng bradykinin after incubation with 0.2 ml fresh plasma for 2 min at 37°C. 
Plasminogen.  Plasminogen was  prepared  by  affinity chromatography  of  100  ml  of  plasma 
utilizing a lysine-Sephadex  column and epsilon aminocaproic  acid elution as described  by Deutsch 
and Mertz  (11). The plasminogen was concentrated, dialyzed overnight at 4°C against 0.003 M PO4 
buffer pH 8.0 containing  0.15 M NaC1, and further fractionated by Sephadex G-100 gel filtration (10). 
The plasminogen peak was pooled, concentrated, and adjusted to 200 tLg/ml for routine use. The 
preparation contained 28 azocaseinolytic U/ml (12). 
a~-Antitrypsin,  al-antitrypsin was  assayed  functionally by its ability to  inhibit the  esterase 
activity of trypsin upon benzoyl-d,l-arginine-p-nitroanilide (13) and was quantitated on a weight 
basis by radial immunodiffusion  against monospecific antibody. 
KaUikrein and Prekallikrein.  Kallikrein was assayed by incubation  of 0.2 ml enzyme source with 
0.2  ml heat-inactivated plasma for 2 min at 37°C and the bradykinin generated  determined by 
bioassay  (2). Prekallikrein was assayed  by incubation of 0.1  ml prekallikrein source with 0.1  ml 
Hageman factor fragments (25 #g/ml)  for 5 rain at 37°C. 0.2 m[ heat-inactivated plasma was then 
added,  the mixture incubated for 2 min at 37°C and the bradykinin generated  determined. 
Plasminogen Activator and Plasminogen Proactivator.  Plasminogen activator was assayed  by 
incubating 20 ttl of plasminogen activator source with 20 td plasminogen (200 t~g/ml) for 1 h at 37°C 
and the plasmin generated determined by fibrin plate (10). Plasminogen proactivator was assayed by 
incubation of  10  td  plasminogen  proactivator  with  10  td  Hageman  factor  fragments  (25 t~g/ml) 
for 10 min at 37°C. 20 ttl plasminogen (200 tL1) was added, the mixture incubated for 1 h at 37°C and 
the plasmin generated  determined. 
Results 
Activation of Pre-PTA and Inhibition of the Activated Enzyme.  1 ml of the 
preparation of pre*PTA (7.5 ttg/ml) was incubated with 10 ttl of Hageman factor 
fragments (0.25 #g) or 10 ttl buffer for 48 h at 4°C. Activation of the pre-PTA was 
observed  only with  the  preparation  containing the  Hageman  factor fragments 
(Table I)  which  corrected  the  deficient plasma from  a  4%  PTA  level  (PTT  11 
min)  to  an  82%  level  as  indicated by  the  PTT  of  2.5  min  in the  presence  or LOUIS  W.  HECK  AND  ALLEN  P.  KAPLAN  1619 
absence of kaolin. Incubation of the Hageman factor fragments with buffer alone 
for 48 h at 4°C did not alter their ability to activate prekallikrein or plasminogen 
proactivator and they had no significant affect upon the partial thromboplastin 
time of PTA-deficient plasma. Before incubation, the mixture of pre-PTA and 
Hageman factor fragments did not shorten the PTT of PTA-deficient plasma 
beyond that of the PTA preparation alone. In this fashion the PTA preparation 
could be activated utilizing only a trace quantity of activated Hageman factor. 
Alkaline disc  gel  electrophoresis and  SDS  gel electrophoresis of the activated 
PTA revealed a  single band indistinguishable from that shown for pre-PTA in 
Fig.  3.  The  same  result  was  obtained  when  equal  volumes  of either  intact 
activated Hageman factor or more concentrated preparations of Hageman factor 
fragments were incubated with pre-PTA for 5 min at 37°C.  Pre-PTA was not 
activated upon incubation with either kallikrein or plasminogen activator and no 
autoactivation was observed when preparations containing a mixture of pre-PTA 
and activated PTA were incubated for 4 h  at 37°C. 
The ability of DFP  and TLCK to inhibit activated PTA was tested  in the 
following fashion. 1/2 ml of activated PTA was incubated for 90 min at 37°C with 
buffer or with each inhibitor at concentrations ranging from 5  ×  10-5  M  to 5  × 
10 -~ M. The mixture was dialyzed against two changes of 4 liters 0.003  M  PO4 
buffer 0.15 M NaC1 for 24 h and assayed for residual PTA activity. Incubation of 
PTA  with  buffer  alone  revealed  a  PTT  of 3  min  indicating  that  the  PTA 
preparation  was  not  inactivated  nonspecifically  during  the  incubation  and 
dialysis steps.  Incubation of activated PTA with increasing concentrations of 
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FIG.  3.  Isoelectric focusing of pre-PTA in polyacrylamide gels run with pH 7-10 ampholytes. 
Beneath is shown a  duplicate gel which was sliced, eluted, and assayed for pH and pre-PTA 
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DFP  revealed  a  dose-dependent  inactivation  of PTA  as  shown  in  Fig.  4.  In 
contrast a  concentration of 10 -3 M  TLCK did not inhibit activated PTA. 
The effect of various trypsin inhibitors upon the coagulant activity of activated 
PTA was next examined.  Incubation of activated PTA with lima bean trypsin 
inhibitor and  ovomucoid trypsin inhibitor at concentrations up to  1 mg/ml did 
not yield inhibition. However, soybean trypsin inhibitor and trasylol could not be 
evaluated because their addition to the reagent mixture without any incubation 
with the PTA preparation inhibited coagulation.  We therefore incubated  z/2 ml 
activated PTA with either buffer,  1/2 ml of soybean trypsin inhibitor (1 mg/ml), 
or  1/2 ml trasylol (10,000 U/ml)  for 30 min at 37°C. The mixtures were dialyzed 
against  0.003 M  PO4 buffer pH 8.0 and each was  passed over a  1.9 cm x  15 cm 
column of QAE  Sephadex. 30 ml of effluent were collected and concentrated to 
1.0 ml. This effluent was free of any inhibitors as assessed by the ability of each 
effluent to inhibit the kinin-generating activity of kallikrein or the esterase activ- 
ity of trypsin. The effluents were then assayed for activated PTA. PTA that had 
been incubated with buffer alone had a clotting time of 4 min while the soybean 
TABLE I 
Activation of Pre-PTA  by Hageman Factor Fragments 
Sample  Time of  Reagent added to 
incubation  PTA-deficient plasma  PTT 
h  rain 
Pre-PTA + buffer  48  Cephalin  11 
Pre-PTA .. HFr  None  Cephalin  11 
Pre-PTA + HFf  48  Cephalin  2.5 
Pre-PTA ,, buffer  48  Cephalin .. kaolin  2.5 
Buffer -- HF~  48  Cephalin  10.5 
FIG.  4. 
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trypsin inhibitor and trasylol effluents clotted in 19 min and 12 min respectively 
indicating that both these inhibitors are effective upon activated PTA. 
Identification of a~-Antitrypsin as a Plasma Inhibitor of Activated PTA.  In 
order  to  isolate  the  plasma  inhibitors of activated PTA,  the  QAE  Sephadex 
column  utilized  to  isolate  pre-PTA  was  washed  with  a  series  of buffers  of 
increasing ionic strength, the fractions concentrated to 500 cc, and assayed for 
various  inhibitors  by  electroimmunodiffusion as  indicated  in  Table  II.  PTA 
inhibition  was  not  observed  in  the  0.12  M  NaC1  fraction  which  contained 
a,-macroglobulin; however, inhibition was observed in the 0.2  M NaC1 fraction 
containing a~-antitrypsin, al-antichymotrypsin, antithrombin III, and CT INH, 
and to a lesser degree in the 0.3 M NaC1 fraction which contained inter-a-trypsin 
inhibitor as well as these latter inhibitors in lesser concentration. 
The 0.2 M NaC1 fraction was therefore dialyzed against 0.003 M PO4 buffer pH 
8.1 and applied to a 9 cm x 72 cm column of QAE Sephadex equilibrated with the 
same buffer. The column was first washed with 4 liters of starting buffer and then 
TABLE II 
Isolation of Plasma Inhibitors  by Batch Elution of QAE Sephadex* 
0.003 M  PO,  0.003 M  PO,  0.003 M  PO,  0.003 M  PO° 
0.003 M  PO,  0.06 M  NaC1  0.12 M  NaCl  0.20 M  NaCl  0.30 M  NaCl 
a,-Macroglobulin  -  -  +  - 
a 1-Antitrypsin  -  -  +  ± 
a l-Chymotrypsin  inhibitor  -  -  +  ± 
Anti-thrombin  III  -  -  +  ± 
CT inhibitor  -  -  +  ± 
Inter a-trypsin  inhibitor  -  -  -  + 
* The  location  of each  inhibitor  is  reported  as  either  positive  (+)  or  negative  (-)  as  assessed  by 
electroimmunodiffusion  against  monospecific  antisera  to  each  of the  proteins  sought.  A  fraction 
containing  an inhibitor in lesser concentration  (by inspection) than  the major fraction is designated 
(±). 
washed with 4 liters of 0.003 M PO, buffer pH 8 containing 0.12 M NaC1. A 10 x 
10 liter linear salt gradient was then applied utilizing the buffer containing 0.12 
M  NaC1  as the starting buffer and 0.003  M  PO, buffer pH 8 containing 0.30 M 
NaC1 as the limit buffer. As shown in Fig. 5,  antithrombin III was eluted at a 
conductivity of 19mS  followed by  al-antitrypsin and  al-antichymotrypsin at 
22mS  and somewhat later by CT INH at 26 mS. PTA inhibition was observed 
through  the  entire  region  from  tubes  350-550.  However,  the  peak  activity 
appeared to coincide with the mixture of al-antitrypsin and al-antichymotryp- 
sin. Tubes 400-450  were therefore concentrated to 10.0 ml and fractionated on 
Sephadex G-100 as shown in Fig. 6 A. The optical density observed at 280 mtt was 
due primarily to albumin, a~-antichymotrypsin eluted along the ascending limb 
of the  albumin  peak  at  an  approximate  mol  wt  of 72,000  and  a~-antitrypsin 
eluted along the descending limb of the albumin peak and had an estimated mol 
wt of 65,000.  Gel filtration of CT INH reveals a mol wt of approximately 175,000; 
it is thus considerably larger and elutes at the void volume of G-100.  When the 1622  SUBSTRATES  OF HAGEMAN FACTOR.  I 
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FIG.  5.  QAE  Sephadex  chromatography  of  the  0.2  M  NaCI  eluate  indicated  in  Table  II 
demonstrating the elution profile of the four a-globulin inhibitors. The inhibitors were located 
by electroimmunodiffusion  against monospecific antisera and the elution profile estimated by 
inspection  utilizing  a zero to +4 scale. The dashed line indicates the conductivity of the salt 
gradient between zero and 38mS. 
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FIG. 6.  (A) Sephadex  G-100 gel filtration of the concentrate of tubes 400-450 obtained from 
QAE Sephadex (Fig. 5). (13) Beneath is shown the assay for inhibition of activated PTA. 
column  was  assayed  for  PTA  inhibition,  the  peak  of  inhibition  observed 
coincided  with  the  elution  profile  of al-antitrypsin  (Fig.  6).  When  tubes  60-80 
were concentrated  to 5  ml,  complete  inhibition  of activated  PTA  was obtained 
(PTT  >  1  h).  However,  the concentrate  contained  detectable  antithrombin  III 
which was not evident when the column was assayed  directly. LOUIS  W.  HECK  AND  ALLEN P.  KAPLAN  1623 
The  concentrate was  then  passed  over  a  5  cm  x  12  cm  column of Con  A 
Sepharose in order to bind al-antitrypsin via its carbohydrate moiety (14). The 
effluent contained albumin and al-chymotrypsin inhibitor and was concentrated 
back to 5 ml in order to assay it for PTA inhibitory activity. This effluent did not 
inhibit activated PTA, thus archymotrypsin inhibitor did not contribute to the 
inhibitory activity of the G-100 fraction. The column was next eluted with 150 cc 
0.1  M  methyl-a-D glucopyranoside, the  eluate concentrated to 5  ml,  dialyzed 
against  0.003  M  PO~  buffer  0.15  M  NaC1,  and  assayed  for  arantitrypsin, 
antithrombin III, and PTA inhibitory activity. This fraction possessed all of the 
PTA inhibitory activity and contained 2.5 mg/ml a~-antitrypsin. By electroim- 
munodiffusion antithrombin III was also detectable; however, its presence at this 
stage of purification was variable. In order to remove any residual antithrombin 
III and other trace contaminants, this fraction was recycled on a 3.8 cm x 42 cm 
column of QAE  Sephadex column run in the same fashion as described above 
utilizing  a  gradient  of  2  liters  in  each  bucket.  Only  the  peak  tubes  of 
arantitrypsin as assayed by quantitative immunodiffusion  were then pooled and 
concentrated to 2 mg/ml. Polyacrylamide gel electrophoreses of the a~-antitryp- 
sin preparation after the Sephadex G-100 step, Con A Sepharose step, and final 
QAE Sephadex step are shown in Fig. 7. The final preparation contained a single 
band which was shown to represent  arantitrypsin by elution and assay of an 
unstained disc gel run simultaneously. The preparation was then serially diluted 
and 25  pl of each dilution incubated with 25 ~1 of purified activated PTA  (10 
~g/ml)  for  20  min  at  37°C  and  assayed  for  residual  activated  PTA.  A 
dose-response  inhibition was obtained as shown in Fig. 8;  inhibition was first 
detectable at a~-antitrypsin concentrations of 25-30 ug/ml. At the upper limit of 
normal  plasma  concentration  (4,400  gg/ml)  complete  inhibition  of PTA  was 
obtained since the preparation did not clot in over 1 h. A time course of inhibition 
was  performed  utilizing  1,200  gg/ml  arantitrypsin  incubated  with  20  #g/ml 
activated PTA as shown in Fig. 9. Essentially no inhibition of activated PTA was 
obtained if it was mixed with arantitrypsin but not incubated; as the incubation 
time at 37°C was increased, inhibition was observed such that the PTT at 30 min 
was 10 min compared to an initial PTT of 2 min 20 sec. 
In order to confirm that a~-antitrypsin is definitely responsible for the observed 
PTA inhibition, 50 cc of either normal plasma (a~-anti-trypsin 3,200  #g/ml) or 
a~-antitrypsin-deficient plasma  (a~-antitrypsin  <  2  #g/ml)  were  fractionated 
through the Gol00 step and assayed for PTA inhibition. As shown in Fig. 10, the 
normal  plasma  contained  al  antitrypsin as  well  as  a~-antichymotrypsin and 
antithrombin III (10 A)  and when assayed possessed a  peak of PTA inhibitory 
activity (10  B).  However,  the  a~-antitrypsin deficient plasma  possessed  both 
a~-antichymotrypsin and antithrombin III but no a~-antitrypsin (10 C) and did 
not exhibit a peak of PTA inhibitory activity (10 D). When tubes 50-80 from both 
columns were concentrated and assayed for PTA inhibition, the concentrate from 
the  normal  plasma  gave  complete  inhibition  (PTT  >  1  h).  However,  the 
concentrate  from  the  al-antitrypsin-deficient  plasma  prolonged  the  PTT 
from  2.5  min  to  8  min.  The  PTA  inhibitor  present  in  this  fraction  of the 
arantitrypsin-deficient plasma was isolated by elution from Con A Sepharose 1624  SUBSTRATES OF HAGEMAN FACTOR. 1 
FIG.  7.  Disc  gel  electrophoresis  of  at-antitrypsin  after  each  of  the  final  three  steps  of 
purification. From left to right the gels shown were obtained after chromatography on Sephadex 
G-100,  Con A Sepharose, and rechromatography on QAE Sephadex. 
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FIG.  9.  A  time-course  of  inhibition  of  20  •g  activated  PTA  by  al-antitrypsin  at  a 
concentration of 1,200 ~g/ml. 
and  rechromatography  on  QAE  Sephadex.  This  inhibitor  was  identified  as 
antithrombin  III by its elution position on QAE Sephadex and alkaline disc gel 
electrophoresis and its enhanced activity after incubation with heparin  (7). 
Discussion 
Recently, considerable progress has been made in the isolation of the substrates 
of activated Hageman factor both as activated enzymes and in precursor form. 
The first chromatographic  separation of activated PTA from kallikrein  (15) and 
pre-PTA  from  prekallikrein  (8)  was achieved  by Kaplan  and  Austen  utilizing 
sulfoethyl Sephadex.  Harpel also prepared  activated PTA free of kallikrein  by 
incubating the mixture with a~-macroglobulin and then separating the activated 
PTA from the kallikrein-a2-macroglobulin  complex (16). Three step procedures 
for the isolation of pre-PTA were then reported (10, 17) utilizing QAE Sephadex, 
Sephadex  G-150,  and  SP  Sephadex  or utilizing  Pevikon block electrophoresis 
rather  than  a  gel filtration  step  (18).  In the studies  presented  herein,  we have 
found  a  minimum  of four steps  essential  for the  purification  of pre-PTA.  The 
molecule  is  isolated  largely  in  precursor  form  if precautions  are  taken  in  the 
handling  of plasma  in  order  to  minimize  activation  of Hageman  factor.  Once 
pre-PTA was obtained in the QAE Sephadex effluent, it was stable and could be 
readily  processed  through  the  other  purification  steps.  A  minimum  of three 
columns were required in order to completely separate it from the other Hageman 
factor substrates prekallikrein  and  plasminogen  proactivator  (10)  since the SP 
Sephadex  concentrate  was invariably  contaminated  with  both these  enzymes; 
pre-PTA is the first substrate eluted from Sephadex G-150 and it is thereby then 
obtained free of these trace contaminants.  After these three steps approximately 
80%  of the  protein  content  is  still  due  to  IgG  which  is  completely  removed 
utilizing  the  immunoadsorbant.  Approximately 20% of the  plasma  pre-PTA  is ELECTROIMMUNODIFFUSION 
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recovered  after  the  three  chromatographic  steps  and  further  losses  during  the 
immunoadsorbant step yields a  final recovery of 10-15%. 
The activation of pre-PTA has been shown by Ratnoff et al. to be dependent upon the 
activation of Hageman factor (1). We have utilized trace quantities of purified Hageman 
factor  fragments  to  activate  pre-PTA  suggesting  that  the  activation  observed  is  an 
enzymatic reaction  and that a  stable complex between activated Hageman factor and 
PTA  does  not  form.  This  is  consistent  with  the  data  of  others  (10,  15,  17-19) 
demonstrating  that  the  physicochemical  properties  of activated  PTA  does  not  differ 
significantly from that of the  precursor  molecule.  A  mechanism of limited  proteolytic 
digestion  of pre-PTA  by  activated  Hageman  factor  is  thus  suggested.  Wuepper  has 
demonstrated  that  reduction  and  alkylation  of  activated  PTA  prepared  by  trypsin 
activation  of pre-PTA  does  not  yield  the  same subunit  structure  of that  of pre-PTA 
suggesting that cleavage of one or more bonds occurred concomitantly with  activation 
(18).  The conversion of pre-PTA to activated PTA by the Hageman factor prealbumin 
fragments  indicates  that  this  enzyme  possesses  the  active  site  for  the  activation  of 
pre-PTA as well as its known activity upon prekallikrein (2) and plasminogen proactivator 
(10)  and  confirms  the  observation  that  these  fragments  possess  coagulant  activity 
identifiable as Hageman factor (2,  20).  Recently Schiffman and Lee have reported that 
they are unable to activate highly purified Factor XI with a crude preparation of partially 
activated Hageman factor or with kaolin absorbed Hageman factor and suggested that 
another factor is required for Factor XI activation (21);  we have not observed evidence of 
such a requirement. The active site of activated PTA apparently contains a critical serine 
which is inhibitable by DFP but does not possess a histidine which is readily susceptible to 
TLCK. Utilizing an esterase assay for activated PTA, inhibition has been observed with 
soybean and pancreatic trypsin inhibitors (18).  However, these inhibitors are difficult to 
evaluate in a coagulation assay. By reisolating activated PTA after incubation with each 
inhibitor, we could assess their effect upon its coagulant activity and found that soybean 
trypsin inhibitor and trasylol are inhibitors of the coagulant activity of activated PTA, 
whereas ovomucoid and  lima bean trypsin inhibitors are not. This inhibition  profile of 
DFP, TLCK, and trypsin inhibitors is identical to that obtained with plasma kallikrein. 
When we sought the plasma inhibitors of activated PTA, we found that the major 
peak of inhibitory activity did not  correspond to  CT INH, a  known inhibitor of 
activated PTA (6). This inhibitor was identified as al-antitrypsin by demonstrat- 
ing  that  throughout  the  subsequent  purification  steps,  the  elution  profile  of 
al-antitrypsin and the PTA inhibitor peak coincided. Although antithrombin III 
has also been identified as a PTA inhibitor (7), its activity is greatly enhanced by 
heparin.  In the absence of heparin,  we did not observe a  peak of PTA inhibition 
coincident with the elution profile of antithrombin III although inhibition by this 
factor was confirmed when fractions containing this protein were concentrated. 
The  prominent  diminution  of  PTA  inhibitory  activity  when  a~-antitrypsin 
deficient  plasma  was  fractionated,  provides  confirmatory  evidence  that  it  is 
a~-antitrypsin  and  not  an  unknown,  closely related  contaminant  which  is  the 
source  of the  inhibition.  Nossel  and  Niemetz  have partially  purified  a  normal 
plasma inhibitor of activated PTA  (22)  which was an a-globulin similar to but 
distinguishable  from antithrombin  III (23)  and  Amir et  al.  (24)  have isolated a 
similar inhibitor of mol wt 65,000 which was clearly distinguishable from CT INH 1628  SUBSTRATES  OF  HAGEMAN  FACTOR.  I 
(25) and contained no apparent antitryptic or antithrombin activity. Thus, there 
may be  yet  another  plasma  PTA  inhibitor  which  possesses  chromatographic 
properties similar to a~-antitrypsin and anti-thrombin III. 
We  have  found  that  a~-antitrypsin  does  not  inhibit  either  kallikrein  or 
plasminogen  activator  which  further  distinguishes activated PTA  from  these 
other Hageman factor substrates.  The weak kallikrein inhibition observed by 
others  to  be  secondary to  a~-antitrypsin  (26) may,  in  fact,  be  secondary to 
contamination by antithrombin III (27). The prominent peak of PTA inhibition 
by a~-antitrypsin observed upon fractionation of human plasma suggests that 
a~-antitrypsin represents one of the major inhibitors of this coagulation factor. 
Summary 
Unactivated  partial  thromboplastin  antecedent  (PTA)  has  been  purified  by 
sequential  chromatography  of  plasma  on  quaternary  aminoethyl  Sephadex, 
sulphoprophyl  Sephadex,  Sephadex  G-150,  and  passage  over  an  anti-IgG 
immunoadsorbant. The  preparation  gave a  single band after alkaline disc gel 
electrophoresis, sodium dodecyl sulfate (SDS) gel electrophoresis and isoelectric 
focusing in acrylamide gels and was found to have a  mol wt of 175,000 by gel 
filtration, 163,000 by SDS gel electrophoresis, and an isoelectric point of 8.8-9.4 
(peak 9.0-9.1). Pre-PTA was activated directly by activated Hageman factor or 
by Hageman factor prealbumin fragments. Its coagulant activity was inhibited 
by DFP,  soybean trypsin inhibitor and trasylol but not by lima bean trypsin 
inhibitor or qvomucoid trypsin inhibitor indicating that activated PTA possesses 
the same inhibition profile utilizing these reagents as does plasma kallikrein. A 
major  plasma  inhibitor  of activated  PTA  was  found  to  be  a  65,000  mol  wt 
a-globulin which was isolated free of a~-chymotrypsin inhibitor, inter a-trypsin 
inhibitor, a2-macroglobulin, and the other known inhibitors of activated PTA, 
the activated first component of complement (CT INH), and antithrombin III. Its 
physicochemical properties were identical to al-antitrypsin, and it was absent in 
al-antitrypsin-deficient  plasma  thereby  identifying  this  PTA  inhibitor  as 
al-antitrypsin. 
Received for publication  1 July 1974. 
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